The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
Phase III trials which pitted Izervay against placebo injections. Some patients received 2 mg of Izervay on a monthly basis while others received the placebo. Researchers evaluated the rate of GA progression at baseline, six months and then 12 months.
Researchers found that participants receiving the Izervay injections had a reduction of up to 35% in their disease progression as early as six months and up into the first year of treatment. Adverse reactions among participants included conjunctival hemorrhage, elevated intraocular pressure and blurred vision.
Iveric Bio, manufacturer of Izervay, hopes to have Izervay available for patients late August 2023.
